Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
about
CXCR7 influences leukocyte entry into the CNS parenchyma by controlling abluminal CXCL12 abundance during autoimmunityCurrent stage in inflammatory bowel disease: What is next?T Cell Migration in Rheumatoid ArthritisTherapeutic approaches for celiac diseaseShining a light on intestinal trafficReview article: anti-adhesion therapies for inflammatory bowel diseaseInflammatory pathways of importance for management of inflammatory bowel diseaseCCL25/CCR9 interactions regulate large intestinal inflammation in a murine model of acute colitisA systemically-administered small molecule antagonist of CCR9 acts as a tissue-selective inhibitor of lymphocyte traffickingA novel CMKLR1 small molecule antagonist suppresses CNS autoimmune inflammatory diseaseCCL25/CCR9 interactions regulate the function of iNKT cells in oxazolone-induced colitis in mice.CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knockin mice.The role of the innate and adaptive immune system in pediatric inflammatory bowel disease.Novel therapies for coeliac diseasePTEN action in leukaemia dictated by the tissue microenvironment.Inhibition of infection-mediated preterm birth by administration of broad spectrum chemokine inhibitor in mice.A randomized controlled trial of the efficacy and safety of CCX282-B, an orally-administered blocker of chemokine receptor CCR9, for patients with Crohn's diseaseThe chemokine receptor CCR9 is required for the T-cell-mediated regulation of chronic ileitis in mice.Granulocyte-macrophage colony stimulating factor blockade promotes ccr9(+) lymphocyte expansion in Nod2 deficient mice.Intraepithelial lymphocytes: to serve and protect.Increased expression of CC chemokine ligand 18 in patients with chronic rhinosinusitis with nasal polyps.Unexpected Regulatory Role of CCR9 in Regulatory T Cell Development.CCR9 Antagonists in the Treatment of Ulcerative Colitis.Characterization of Pharmacologic and Pharmacokinetic Properties of CCX168, a Potent and Selective Orally Administered Complement 5a Receptor Inhibitor, Based on Preclinical Evaluation and Randomized Phase 1 Clinical Study.CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone diseaseLeukocyte Trafficking to the Small Intestine and ColonGranulocyte-macrophage colony-stimulating factor autoantibodies: a marker of aggressive Crohn's diseaseInternational Union of Basic and Clinical Pharmacology. [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors.Effects of vercirnon on the activity of CYP3A4, CYP2C19 and CYP2C8 enzymes and BCRP and OATP1B1 transporters using probe substrates.C5a receptor (CD88) blockade protects against MPO-ANCA GNHow does knowledge from translational research impact our clinical care of pediatric inflammatory bowel disease patients?Modifying T-cell trafficking to the intestinal as a potential management for inflammatory bowel disease.The immunopathogenesis of celiac disease reveals possible therapies beyond the gluten-free diet.Evolving molecular targets in the treatment of nonmalignant gastrointestinal diseases.Targeting T-cell migration in inflammatory bowel disease.Inhibition of selective adhesion molecules in treatment of inflammatory bowel disease.Latest in vitro and in vivo models of celiac disease.Involvement of CXCR4/CXCR7/CXCL12 Interactions in Inflammatory bowel disease.Progress in the discovery of CC chemokine receptor 2 antagonists, 2009 - 2012.Vercirnon for the treatment of Crohn's disease.
P2860
Q24621645-1260E6DE-D89B-4A57-BDC8-48FDE8D82B2BQ26777429-101794D5-17FA-4CAA-9EE4-A552220BE60AQ26797338-DDB2B529-061D-407D-91D5-D6FE903F2215Q26825413-82006A9C-8B5D-41F7-9FF9-719EA6ED8F17Q26863227-81A1F100-134B-40FB-89CC-A68D43A78677Q26999705-A03CA2B3-B0FF-479D-8178-5C993862FE69Q27005445-F82FDD41-BD42-44FB-9193-71146D5DA858Q27437634-AD20B0E5-3D8D-47A3-BADE-75734EE0523CQ28485386-336709D7-5E4A-441C-B060-51B22B318B04Q28542368-463CED64-7F30-4323-93AD-87916B26676EQ33769231-6BE012C2-2368-4BBE-A391-6E5A217FF2C1Q33816616-DAF0D974-C0A3-48E3-B6FB-BD657B1261E1Q33830707-3AB94E4A-74EF-4468-9183-0EDAF314528EQ34170574-6B027025-7962-4F14-8907-1290F21BDD64Q34196262-EDACB372-224D-489B-8462-79FE57947937Q34336857-028F7567-62F7-4385-A9AE-4FB0C22432A8Q34635636-1675F826-FFE3-48C1-91D3-7BAB6049B7C2Q34916935-AE044B89-7994-4AF1-90AA-41EE8C44BD48Q35036733-6CD945CD-AAA6-4BDB-8DDF-615B132F86D2Q35573805-CE00DCBA-C5B0-43D0-8D32-389E11DFE395Q35634156-786C413D-3F1B-40F4-9AB6-0AA632F5ED97Q35730792-531CE5D6-9CC7-4747-ADD0-EE48820673F0Q36118943-23CDA567-378C-4C4B-9AC9-1C758F6324CAQ36170691-8F626B7C-58B3-4203-91DD-DC07354B4BBAQ36177928-C704CC58-A59B-4527-B2E4-0D4F15DC357BQ36592984-09E85B55-0FF6-47D1-ACDC-A9E54693B9A3Q36999645-00EB8C14-F4C3-4F33-94E8-911CE8730720Q37432097-8C860407-5BAE-49A2-A911-011A76EEE6A1Q37469352-603E90FD-E81D-4F1E-849B-BFB10C0589F0Q37524080-5A1EF9CD-10CB-456B-AD78-A3FFA1136717Q37994130-3C843C3E-456B-48B2-8C1F-E4FC5AA5D3FDQ38011773-23D27FA5-1947-42C0-8534-AA7F97525D86Q38016781-0D8E05FF-3EE4-4D6B-A42B-E1F9B0FB4F8DQ38029235-CD953B04-135F-4677-8024-B035BC57F71BQ38040430-59B928B6-A332-481D-8D8A-B10DA9567042Q38053495-2628063D-A7CF-42BD-831A-53CC97581B08Q38072065-A14314F4-6CFB-4066-8E33-AE811CAE5F6AQ38079237-9BE58686-98AB-4523-BDC7-BE0459C52813Q38083321-25ADBF4C-6097-4D75-9109-EA947A8FCE65Q38102750-67785F77-2B35-4F41-B8F5-CA5A2B5889C2
P2860
Characterization of CCX282-B, an orally bioavailable antagonist of the CCR9 chemokine receptor, for treatment of inflammatory bowel disease.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Characterization of CCX282-B, ...... of inflammatory bowel disease.
@en
Characterization of CCX282-B, ...... of inflammatory bowel disease.
@nl
type
label
Characterization of CCX282-B, ...... of inflammatory bowel disease.
@en
Characterization of CCX282-B, ...... of inflammatory bowel disease.
@nl
prefLabel
Characterization of CCX282-B, ...... of inflammatory bowel disease.
@en
Characterization of CCX282-B, ...... of inflammatory bowel disease.
@nl
P2093
P356
P1476
Characterization of CCX282-B, ...... of inflammatory bowel disease.
@en
P2093
Andrew Pennell
Bin N Zhao
Daniel J Dairaghi
Emily Wendt
J J Kim Wright
Juan C Jaen
Linda S Ertl
Mark E T Penfold
Matthew J Walters
P356
10.1124/JPET.110.169714
P407
P577
2010-07-21T00:00:00Z